Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.

Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.

<h4>Background</h4>Parkinson disease (PD) psychosis (PDP) is a disabling non-motor symptom. Pharmacologic treatment is limited to pimavanserin, quetiapine, and clozapine, which do not worsen parkinsonism. A Food and Drug Administration black box warning exists for antipsychotics, suggest...

Full description

Bibliographic Details
Main Authors: Katherine Longardner, Brenton A Wright, Aljoharah Alakkas, Hyeri You, Ronghui Xu, Lin Liu, Fatta B Nahab
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0278262

Internet

https://doi.org/10.1371/journal.pone.0278262

Similar Items